PRESCRIPTION PATTERN AND COST OF ILLNESS (COI) OF INFLAMMATORY BOWEL DISEASE (IBD) IN A TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.22159/ijpps.2017v9i1.14248Keywords:
IBD, COI, Prescription Pattern, PharmacoeconomicsAbstract
Objective: Treatment of Inflammatory Bowel disease (IBD) centers on agents used to relieve inflammatory process. None of the drugs used for IBD are curative; at best they serve to control the disease process. The potentially high costs of care associated with inflammatory bowel disease (IBD) are recognised. The Objective of the present study was to find the Prescription pattern and cost of illness (COI) of IBD in a Tertiary care Hospital.
Methods: 20 IBD patients, in the order they approached the gastroenterology department, were enrolled in the study. Data regarding medication, hospitalisation, physician office visit, diagnostic costs, travel cost, the cost incurred by caregivers, work and non-work days lost were obtained. The cost of medications and other healthcare services was determined. The study was approved by the Institutional ethics committee.
Results: The average cost (direct and indirect) per patient for six months was 26,394Rs. Drugs and medical supplies costs (65%) ranked first in the direct costs category followed by Diagnostic costs (18%), hospitalisation costs (15%) and lastly physician office visit costs (2%). On the other hand, Cost incurred by caregivers accounted for 45% of the total indirect costs followed by work and nonworking days lost (43%) and finally Travel costs (2%). Commonly prescribed drugs were corticosteroids and aminosalicylates followed by mucosal protectants, antibiotics and antiemetics. The most preferred route of drug administration was intravenous followed by oral.
Conclusion: The average COI (direct and indirect) of IBD per patient for six months was 26,394Rs. Drugs and medical supplies accounted for largest contributions to the overall economic impact of IBD on the Healthcare system. Commonly prescribed drugs were corticosteroids and aminosalicylates followed by mucosal protectants, antibiotics and antiemetics. This study represents one of the very few studies conducted on COI of IBD. Large scale studies on economic research are required to further ascertain the impact of Rival therapies and management strategies for IBD.
Downloads
References
J Satsangi, MS Silverberg, S Vermeire, JF Colombel. The montreal classification of Inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
C Abraham, JH Cho. Inflammatory bowel disease: N Engl J Med; 2009. p. 2066–78.
Mario Guslandi. A natural approach to the treatment of inflammatory bowel disease. Br J Clin Pharmacol 2008;65:468–9.
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002;8:244–50.
Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471–8.
Juan J, Estiarte R, Colomé E, Artés M, Jiménez FJ, Alonso J. Burden of illness of crohn’s disease in spain. Dig Liver Dis 2003;35:853–61.
Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 y of follow-up evaluation. Gastroenterol 2006;131:719–28.
Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a canadian burden of illness review. Can J Gastroenterol 2012;26:811-8.
BD Lovasz, PA Golovics, Z Vegh, PL Lakatos. New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe. Dig Liver Dis 2013;45:269–76.
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.
www.ccfa.org. Crohn’s and Colitis foundation of America. [Last accessed on 3 May 2016]
Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797–814.
Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134–9.
Paweł W Petryszyn, Izabela Witczak. Costs in inflammatory bowel diseases. Prz Gastroenterol 2016;11:6–13.
Feagan BG, Vreeland MG, Larson LR, Bala MV. The annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000;95:1955–60.
Published
How to Cite
Issue
Section
